Form 4: Xenon Pharma CEO Sells Shares Under 10b5-1 Plan

Xenon Pharmaceuticals Inc.'s President and CEO, Ian Mortimer, sold 97 common shares for $45.01 each on November 28, 2025, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Ian Mortimer, President & CEO and Director of Xenon Pharmaceuticals Inc. (XENE), reported a sale of common shares.
• On November 28, 2025, Mortimer sold 97 common shares at a price of $45.01 per share.
• The transaction was executed under a Rule 10b5-1 trading plan established on September 27, 2024.
• Following the sale, Mortimer directly beneficially owns 31,205 common shares and indirectly owns 14,300 common shares through his spouse.

Sentiment

Score: 5

Explanation: This is a routine insider sale under a 10b5-1 plan, involving a very small number of shares, which is generally considered neutral and not indicative of significant positive or negative sentiment.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate insider information.

Negatives

• Ian Mortimer, President & CEO, sold 97 common shares of Xenon Pharmaceuticals Inc.

Future Outlook

NA

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024.

Industry Context

NA

Related Party Transactions

• Ian Mortimer indirectly beneficially owns 14,300 common shares through his spouse.

Stakeholder Impact

• Shareholders: Minimal impact due to the small number of shares sold and the pre-planned nature of the transaction.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled sale of a very small number of shares by the CEO under a 10b5-1 plan. Such a transaction is not indicative of any significant change in company fundamentals or management's outlook and therefore does not warrant a change in investment recommendation.

Keywords

Xenon Pharmaceuticals, XENE, insider trading, Form 4, stock sale, CEO, 10b5-1 plan, Ian Mortimer